Ever Health Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 6.76 Cr
as on 08-07-2024
- Paid Up Capital ₹ 6.72 Cr
as on 08-07-2024
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 11.43 Cr
as on 08-07-2024
- Satisfied Charges ₹ 20.44 Cr
as on 08-07-2024
- Revenue -38.03%
(FY 2022)
- Profit -50.04%
(FY 2022)
- Ebitda -12.63%
(FY 2022)
- Net Worth 3.06%
(FY 2022)
- Total Assets -6.93%
(FY 2022)
About Ever Health Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 6.76 Cr and a paid-up capital of Rs 6.72 Cr.
The company currently has active open charges totaling ₹11.43 Cr. The company has closed loans amounting to ₹20.44 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkata Kalidindi and Vinod Penmetsa serve as directors at the Company.
- CIN/LLPIN
U24233AP2008PTC059985
- Company No.
059985
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2008
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Vijayawada, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ever Health Life Sciences?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Venkata Kalidindi | Director | 04-Jul-2008 | Current |
Vinod Penmetsa | Director | 27-Aug-2009 | Current |
Financial Performance and Corporate Structure Insights of Ever Health Life Sciences.
Ever Health Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 38.03% decrease. The company also saw a substantial fall in profitability, with a 50.04% decrease in profit. The company's net worth moved up by a moderate rise of 3.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Ever Health Life Sciences?
In 2022, Ever Health Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
Lender | Amount | Status |
---|---|---|
City Union Bank Limited Creation Date: 30 Nov 2022 | ₹11.34 Cr | Open |
Others Creation Date: 12 Dec 2020 | ₹0.95 M | Open |
Canara Bank Creation Date: 22 Jun 2020 | ₹2.72 Cr | Satisfied |
How Many Employees Work at Ever Health Life Sciences?
Unlock and access historical data on people associated with Ever Health Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ever Health Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ever Health Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.